CLINICAL DATA
20+ years of clinical validation.
200 research collaborations. 100s of publications.
About Horizon 2020
Horizon 2020 believes that research is an investment, and is offering different companies and institutions almost €80 billion worth of grants from 2014 to 2020 – that’s in addition to the private investment that this money will attract. The program supports research projects in developing world-class science and innovation, making it easier for public and private sectors to work together. The aim is to enable more breakthroughs, discoveries, and world-firsts by taking great ideas from the lab to the market.
Primary Project Objectives
- Gather additional clinical evidence on the prognostic value (the likely course of breast cancer in an endocrine therapy-treated individual) of MammaPrint (work package 2 – ABCSG 8 trial)
- Obtain additional clinical evidence on the predictive value (identify sub-populations of patients who are most likely to respond to a given therapy) of MammaPrint (work package 3 – STO high risk trial)
- Collect additional clinical evidence on the clinical utility (the likelihood that the test will, by prompting an intervention, result in an improved health outcome) of MammaPrint (work package 3 – STO high risk trial)
-
Demonstrate adherence to the test results in breast cancer patients (work package 5 – PRospective study to measure the Impact of MammaPrint on adjuvant treatment [PRIMe])
- Determine required preconditions for full scale adoption in European and North American markets (work package 6 – communication and dissemination)
